Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of Active Pharmaceutical Ingredients (API) for cancer treatment are driven by the increasing prevalence of cancer worldwide and the continuous demand for effective drugs to combat it. APIs are the key components in pharmaceutical formulations that exert therapeutic effects.
Growing Prevalence of Cancer: Cancer remains one of the leading causes of death globally, with incidences rising steadily. This prevalence fuels the demand for APIs used in cancer treatments, such as chemotherapy drugs and targeted therapies.
R&D Investments and Innovation: Pharmaceutical companies invest heavily in research and development (R&D) to discover novel APIs with enhanced efficacy and fewer side effects. This focus on innovation drives market growth as new and improved cancer treatments enter the market.
Regulatory Landscape: The API market is heavily regulated by health authorities worldwide to ensure the safety and efficacy of cancer drugs. Compliance with regulatory standards, such as Good Manufacturing Practices (GMP), significantly influences market dynamics, as non-compliance can lead to product recalls and legal repercussions.
Competition Among API Manufacturers: The market for cancer APIs is highly competitive, with numerous manufacturers vying for market share. Competition intensifies as companies strive to develop superior products and secure lucrative contracts with pharmaceutical companies producing finished dosage forms.
Supply Chain Challenges: The global supply chain for APIs faces challenges, including raw material sourcing, manufacturing disruptions, and transportation constraints. These factors can impact market dynamics by affecting product availability, pricing, and lead times.
Technological Advancements: Advances in pharmaceutical manufacturing technologies, such as continuous manufacturing and bioprocessing, contribute to market dynamics by improving production efficiency and reducing costs.
Emerging Markets: Emerging economies present significant growth opportunities for API manufacturers due to increasing healthcare spending and expanding access to cancer treatments. However, market dynamics in these regions are influenced by factors such as regulatory requirements and intellectual property rights.
Market Consolidation: Mergers, acquisitions, and strategic partnerships among pharmaceutical companies and API manufacturers shape market dynamics by influencing industry concentration and market competitiveness.
Pricing Pressures: Price competition among API manufacturers and pressure from healthcare payers to reduce drug costs impact market dynamics. Strategies such as volume discounts, value-based pricing, and market segmentation are employed to navigate pricing challenges.
Clinical Trials and Approval Processes: The successful completion of clinical trials and regulatory approval processes significantly impacts market dynamics by determining the commercial viability of new cancer APIs. Delays or failures in these processes can hinder market growth and profitability.
Patient Preferences and Healthcare Trends: Patient preferences for oral therapies, personalized medicine, and convenient drug administration methods influence market dynamics by shaping demand for specific API formulations and delivery systems.
Global Economic Factors: Economic conditions, currency fluctuations, and healthcare reimbursement policies affect market dynamics by influencing purchasing power, investment decisions, and pricing strategies across different regions.
Impact of COVID-19 Pandemic: The COVID-19 pandemic has disrupted global healthcare systems and supply chains, impacting market dynamics for cancer APIs. Changes in healthcare priorities, regulatory responses, and patient behaviors have reshaped market trends and demand patterns.
Future Outlook: The market dynamics of Active Pharmaceutical Ingredients for cancer treatment are expected to continue evolving in response to scientific advancements, regulatory changes, and shifts in healthcare priorities. Continued innovation, strategic collaborations, and adaptation to emerging trends will be crucial for companies to thrive in this dynamic market landscape.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Active Pharmaceutical Ingredient for Cancer Market Highlights:
Active Pharmaceutical Ingredient for Cancer Market Synopsis
The Active Pharmaceutical Ingredient (API) for Cancer market is projected to reach USD 250191.59 Million by 2030 at 7.40% CAGR during the forecast period 2022-2030 API for cancer market, including conventional syringes, needle-free injectors, and auto and pen injectors have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The market for API for cancer has witnessed continuously rising R&D. As a result, the active pharmaceutical ingredient for cancer market is fragmented into various advanced products as per the molecules. Following the illustrated course, it is projected that increasing prevalence of cancer, growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs drives the market growth. However, side effects associated with the medication are estimated to restrain the market growth during the forecast period.
Active Pharmaceutical Ingredient for Cancer Market Dynamics
The active pharmaceutical ingredient for cancer market is driven by increasing prevalence of cancer drives the market growth. According to the statistical report published by the World Health Organization (WHO) in 2018, around 18.1 million new cases of cancers were estimated reported worldwide. This indicates a potential for growth in the global API for cancer market.
The other factors that are driving the global API for cancer market are growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs, and others.
Global Active Pharmaceutical Ingredient for Cancer Market Size, by Indication, 2018 & 2025 (USD Million) Â 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Segmentation
The global API for cancer market has been segmented into by type, indications, and end users.
Based on type it is segmented into tinib, parib, rafenib, lisib, degib, ciclib, and others
Based on indication, it is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others.
Based on end user, the market is segmented into pharmaceutical companies, research organizations, others.
Active Pharmaceutical Ingredient for Cancer Market Key Players
The prominent players in the global API for cancer market are AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.
Global Active Pharmaceutical Ingredient for Cancer Market Share, by Region, 2018 (%) Â 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Regional Analysis
The global API for cancer market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is anticipated to dominate the global API for cancer market owing to the rising awareness about the condition and high healthcare expenditure. The Americas is expected to reach USD 34,300.00 million by 2025 at a CAGR of 8.1% from 2018 to 2025. The Americas region accounted largest regional market owing to the growing biotechnology industry, the growing prevalence of cancer, and a highly developed healthcare sector. Â
Europe accounted for the second-largest market share in 2018 due to extensive R&D for healthcare, increasing funding, and growing adoption of the technology within the region.
On the other hand, the Middle East and Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.
Key Updates
- In May 2019, Eli Lilly and Company received US Food and Drug Administration approval for its drug Cyramza (ramucirumab) a human VEGFR2 antagonist. It is a recombinant molecule of the human IgG1 monoclonal antibody.
- In April 2019 Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor.
Market Segmentation
Global Active Pharmaceutical Ingredient for Cancer Market, by Type
- Tyrosine Kinase Inhibitor (Tinib)
- Ponatinib
- Brigatinib
- Ruxolitinib
- Erlotinib
- Alectinib
- Cobimetinib
- Neratinib
- Osimertinib
- Acalabrutinib
- Bosutinib
- Crizotinib
- Axitinib
- Sunitinib
- Ceritinib
- Imatinib
- Lapatinib
- Afatinib
- Cabozantinib
- Dasatinib
- Ibrutinib
- Lenvatinib
- Gefitinib
- Others
- Proteasome Inhibitors (Parib)
- Olaparib
- Rucaparib
- Niraparib
- BRAF Kinase Inhibitors (rafenib)
- Sorafenib
- Regorafenib
- Vemurafenib
- Dabrafenib
- Enasidenib
- Others
- Phosphatidylinositol 3-Kinase Inhibitors (Lisib)
- Idelalisib
- Copanlisib
- SMO Receptor Antagonists (Degib)
- Sonidegib
- Vismodegib
- Cyclin Dependent Kinase Inhibitors (Ciclib)
- Palbociclib
- Ribociclib
- Abemaciclib
- Others
Global API for Cancer Market, by Indication
- Blood Cancer
- Skin Cancer
- Lungs Cancer
- Breasts Cancer
- Pancreas Cancer
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by End User
- Pharmaceutical Companies
- Research Organizations
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- Supply & Demand Analysis
Intended Audience
- Pharmaceutical Companies
- Hospitals and Clinics
- Regulatory Agencies
- Research Institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
